In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pfizer spin-off RaQualia gets $84mm in funding

Executive Summary

Pfizer spun off RaQualia Pharma, which gets a combined $63mm from top shareholder NIF SMBC Ventures (holds a 32% stake) and Coller Capital (24% ownership) in addition to $21mm from Pfizer for a 19% stake. Seven other investors are backing RaQualia as well.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies